AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

Venclexta (venetoclax) is a prescription drug that’s used to treat certain blood cancers. Venclexta comes as an oral tablet. Venclexta is used in adults to treat the following cancers in certain ...

The study evaluated a combination therapy involving its blockbuster cancer drug Venclexta (venetoclax) in newly diagnosed patients with higher-risk myelodysplastic syndrome (MDS). The VERONA study ...